PureTech Health
PRTC · Main Market · Health Care · mcap £262m · 111.0p
PureTech founds and part-owns biotech companies, developing some programmes itself before spinning them into separate 'Founded Entities' funded by outside investors. It earns returns through equity stakes, milestones and royalties.
| Date | Type | Announcement | Day |
|---|---|---|---|
| 09 Oct 26 | PRTC's SPTX Presents Phase 1 GlyphAgo Data at ECNP
Seaport Therapeutics presented Phase 1 data for GlyphAgo showing 6.8-fold bioavailability increase over unmodified agomelatine. |
+2.8% | |
|
Bioavailability increase 6.8-foldPK variability reduction 10-fold lowerPhase 1 trial participants 174 healthy volunteersAUC variability (GlyphAgo) 12.9-26.6%AUC variability (unmodified agomelatine) 200%
|
|||
| 07 Oct 26 | PRTC's SPTX: Phase 2a Trial of GlyphAgo Initiated
Seaport Therapeutics, a PureTech Founded Entity, dosed first patient in Phase 2a trial of GlyphAgo for generalized anxiety disorder. |
+1.1% | |
|
GlyphAgo bioavailability increase vs unmodified agomelatine 6.8-fold
|
|||
| 07 Oct 26 | Holding | Holding(s) in Company | |
| 25 Sep 26 | Holding | Holding(s) in Company | |
| 22 Sep 26 | Results | Half-year Results
Half-year results show progress across portfolio including Seaport IPO, Celea financing and Phase 3 trial initiation, Gallop FDA clearance. |
−7.3% |
|
PureTech level cash, cash equivalents and short-term investments $220.0 million ($277.0 million)Consolidated cash, cash equivalents and short-term investments $220.1 million ($277.3 million)Operating expenses (H1 2026) $55.9 million ($49.8 million)Seaport holdings valuation approximately $360 millionCelea financing completed $180 millionOperational runway at least through end of 2028
|
|||
| 21 Sep 26 | PRTC's Gallop: Positive FDA Meeting & Fast Track
LYT-200 receives FDA Fast Track designation and clears End-of-Phase 1 meeting for R/R HR-MDS treatment. |
−1.3% | |
|
Overall response rate (Phase 1b, 12mg/kg) 45.5%Complete response rate (Phase 1b, 12mg/kg) 27.3%Complete + partial response rate (Phase 1b, 12mg/kg) 36.3%STRIDE-MDS trial patient enrollment target approximately 125 patientsConversion to transplant rate (Phase 1b, 12mg/kg) 18%Dose-limiting toxicities (Phase 1b) None
|
|||
| 18 Sep 26 | Holding | Holding(s) in Company | |
| 09 Sep 26 | PRTC's SPTX: New Positive Phase 1 GlyphAllo Data
Seaport's GlyphAllo met primary endpoint in Phase 1 driving simulation trial, showing no next-morning driving impairment. |
−0.5% | |
|
GlyphAllo evening dose tested 375 mgSecondary dose tested 250 mgHealthy volunteers enrolled 33Primary endpoint result Met - no driving impairment at 375 mg on Day 5Secondary endpoint result Met - no driving impairment at 250 mg on Day 2
|
|||
| 04 Sep 26 | Holding | Holding(s) in Company | |
| 04 Sep 26 | Routine | Notice of Results | |
| 01 Sep 26 | Routine | Total Voting Rights | |
| 28 Aug 26 | Holding | Holding(s) in Company | |
| 25 Aug 26 | PRTC's Celea:2 Deupirfenidone Presentations at ERS
Celea to present Phase 3 SURPASS-IPF trial design and drug-drug interaction data at ERS Congress in September. |
+2.0% | |
| 18 Aug 26 | Director dealing | PDMR Notification RSU Vesting | |
| 03 Aug 26 | Routine | Total Voting Rights | |
| 31 Jul 26 | Director dealing | PDMR Notification RSU Vesting | |
| 17 Jul 26 | Director dealing | PDMR Notification RSU Vesting | |
| 13 Jul 26 | Celea Doses 1st Patient in Phase 3 IPF Trial
Celea doses first patient in Phase 3 SURPASS-IPF trial comparing deupirfenidone to pirfenidone for IPF treatment. |
+2.7% | |
|
Financing completed $180 millionTrial design Global Phase 3, head-to-head vs pirfenidoneExpected enrollment Approximately 1,100 patientsTrial duration 52 weeksCountries participating More than 30Topline data expected Second half of 2029
|
|||
| 09 Jul 26 | Director dealing | Director/PDMR Shareholding | |
| 02 Jul 26 | PRTC Launches Celea w/ $180M & Top Tier Syndicate
Celea Therapeutics completes $180m funding led by RA Capital, Leaps by Bayer to advance IPF drug deupirfenidone into Phase 3. |
−5.9% | |
|
Financing raised $180 millionPureTech ownership stake in Celea 35.4%PureTech cash contributed $30 millionPureTech reserved for future Celea support $70 millionPotential milestone payments to PureTech up to $190 millionRoyalty rates on net sales 1-3% tiered
|
|||
| 02 Jul 26 | $180M & Asset Transfer
PureTech completes $180m financing for Celea Therapeutics, retaining 35.4% stake and non-dilutive economics. |
−5.9% | |
|
Celea financing raised $180mPureTech's investment in Celea $30mPureTech ownership stake in Celea 35.4%Cash reserved for future Celea support $70mSeries Seed share price $1.93 per share
|
|||
| 10 Jun 26 | Routine | Result of AGM | |
| 09 Jun 26 | PRTC's SPTX: New Positive GlyphAgo Ph1 Dosing Data
Seaport's GlyphAgo Phase 1 trial shows positive safety and tolerability data, supporting advance to two parallel Phase 2 trials. |
−0.5% | |
|
Phase 1 trial participants 174Bioavailability increase vs unmodified agomelatine 6.8-foldPK variability reduction vs unmodified agomelatine 10-fold lower
|
|||
| 04 Jun 26 | Holding | Holding(s) in Company | |
| 29 May 26 | Holding | Holding(s) in Company | |
| 27 May 26 | Holding | Holding(s) in Company | |
| 22 May 26 | Holding | Holding(s) in Company | |
| 15 May 26 | Routine | Correction - Holding(s) in Company | |
| 13 May 26 | PRTC To Showcase Deupirfenidone at ATS Conference
PureTech to present deupirfenidone data at ATS conference, including Phase 3 head-to-head trial design against pirfenidone. |
+1.7% | |
| 08 May 26 | Holding | Holding(s) in Company | |
| 07 May 26 | Holding | Holding(s) in Company | |
| 01 May 26 | PureTech's Seaport Prices Upsized IPO Nasdaq: SPTX
PureTech's founded entity Seaport Therapeutics prices upsized IPO at $18.00 per share on Nasdaq. |
+8.8% | |
|
at the top of the target range expectations IPO price per share $18.00Shares offered 14,160,000Gross proceeds $254.9 millionPureTech's stake post-closing 16,685,013 shares
|
|||
| 29 Apr 26 | Results | Final Results
PureTech announced full-year 2025 results with cash of $277.1m and runway through end-2028; deupirfenidone advanced to Phase 3 readiness. |
−4.2% |
|
PureTech level cash, cash equivalents and short-term investments $277.1 millionPureTech level cash and cash equivalents $248.1 millionOperational runway at least through end of 2028Celea Therapeutics economic interest 100%Seaport Therapeutics economic interest 35.0% equity
|
|||
| 29 Apr 26 | PRTC Voluntarily Delists Nasdaq Depositary Shares
PureTech voluntarily delists American Depositary Shares from Nasdaq, retaining London Stock Exchange primary listing. |
−4.2% | |
| 27 Apr 26 | Holding | Holding(s) in Company | |
| 27 Apr 26 | PRTC's Seaport Adds Neuropsychiatry Veteran to BOD
Seaport Therapeutics appoints Dr. Sharon Mates, former Intra-Cellular Therapies founder and CEO, to its Board of Directors. |
+2.1% | |
|
Intra-Cellular Therapies acquisition price $14.6 billionCAPLYTA sales prior to acquisition >$1.5 billion
|
|||
| 24 Apr 26 | Holding | Holding(s) in Company | |
| 22 Apr 26 | PRTC's Gallop: Positive Ph1 Topline MDS & AML Data
LYT-200 Phase 1b trial shows complete responses in relapsed/refractory MDS and AML with favorable safety profile. |
−1.4% | |
|
Patients evaluated 101R/R HR-MDS overall response rate 45.5%R/R HR-MDS complete response rate 27.3%R/R AML overall response rate 60.0%R/R AML complete response rate 33.3%
|
|||
| 16 Apr 26 | Holding | Holding(s) in Company | |
| 16 Apr 26 | Holding | Holding(s) in Company | |
| 13 Apr 26 | Routine | Notice of Results | |
| 13 Apr 26 | PRTC's Seaport Files for Proposed Nasdaq IPO
PureTech's founded entity Seaport Therapeutics files for Nasdaq IPO via SEC Form S-1 registration. |
+7.2% | |
| 02 Apr 26 | Results | PRTC Publishes Phase 2b Deupirfenidone IPF Results
Phase 2b deupirfenidone trial met primary endpoint, slowing lung function decline versus placebo in IPF patients. |
+2.7% |
|
FVC decline difference vs placebo at 26 weeks 91 mLDeupirfenidone FVC decline over 26 weeks -21.5 mLPosterior probability of superiority vs placebo (FVC) 98.5%Posterior probability of superiority vs placebo (FVCpp) 99.6%Time to IPF progression hazard ratio 0.439Participants remaining on deupirfenidone at 26 weeks 78.1%
|
|||
| 02 Apr 26 | PRTC's Seaport: Positive Topline Ph1 for GlyphAgo
Seaport's GlyphAgo achieved 6.8-fold bioavailability increase versus unmodified agomelatine in Phase 1, advancing to Phase 2 trials. |
+2.7% | |
|
ahead of target expectations Bioavailability increase vs unmodified agomelatine 6.8-foldProgram target for bioavailability increase 2-foldPharmacokinetic variability reduction 10-foldDose-normalized exposure increase (SAD portion) 9.6 to 14.5-foldPhase 1 trial participants (SAD and crossover) approximately 130
|
|||
| 01 Apr 26 | Routine | Total Voting Rights | |
| 25 Mar 26 | PRTC’s Seaport: GlyphAllo Paper Published
Seaport Therapeutics publishes first-in-human data for GlyphAllo in Science Translational Medicine, supporting Phase 2b trial advancement. |
+0.7% | |
|
GlyphAllo Phase 1 dose range 70-1000 mgPhase 2a proof-of-concept dose 375 mgSalivary cortisol reduction p-value p=0.0001
|
|||
| 13 Mar 26 | Director dealing | PDMR Notification RSU Vesting | |
| 02 Mar 26 | Routine | Total Voting Rights | |
| 25 Feb 26 | PRTC to Present at Leerink Healthcare Conference
PureTech Health to present at Leerink Partners Global Healthcare Conference on 11 March 2026. |
+0.0% | |
| 19 Feb 26 | PRTC's Deupirfenidone Granted FDA & EU ODD for IPF
Deupirfenidone granted FDA and European Commission Orphan Drug Designation for idiopathic pulmonary fibrosis. |
−0.8% | |
|
Phase 2b FVC decline at 26 weeks (deupirfenidone 825mg TID) -21.5 mLPhase 2b FVC decline at 26 weeks (pirfenidone 801mg TID) -51.6 mLPhase 2b FVC decline at 26 weeks (placebo) -112.5 mLDifference vs placebo 91 mL (p = 0.02)52-week FVC decline (open-label extension) -32.8 mLTrial completers enrolled in open-label extension 90%
|
|||
| 06 Jan 26 | PureTech to Present at the JP Morgan Conference
CEO to present at J.P. Morgan Healthcare Conference on January 14, 2026. |
+0.2% | |
| 18 Dec 25 | Board change | PureTech Appoints Robert Lyne as CEO
Robert Lyne appointed CEO effective immediately, previously serving as Interim CEO since July 2025. |
+3.6% |
| 10 Dec 25 | Results of AGM on June 16, 2025 – Update Statement
AGM approval received; 20%+ votes against remuneration report and director re-election; Board engaging with shareholders on governance. |
−1.9% | |
| 10 Dec 25 | Holding | Holding(s) in Company | |
| 08 Dec 25 | Successful FDA Meeting; IPF Phase 3 in 1H26
FDA approves Phase 3 trial design for deupirfenidone in idiopathic pulmonary fibrosis; trial to start H1 2026. |
+1.5% | |
|
Phase 2b FVC decline at 26 weeks (deupirfenidone 825mg) -21.5 mLPhase 2b FVC decline at 26 weeks (pirfenidone) -51.6 mLPhase 2b FVC decline at 26 weeks (placebo) -112.5 mLPhase 2b open-label extension FVC decline over 52 weeks -32.8 mLPhase 2b trial enrolment in open-label extension 170 participants (>90%)
|
|||
| 05 Dec 25 | PRTC's Gallop: Positive Initial Topline AML Data
Gallop Oncology reports positive Phase 1b data for LYT-200 in relapsed/refractory AML with 13.2 month median overall survival. |
−0.2% | |
|
exceeded expected late-line survival expectations Combined complete response rate (combination cohort, Phase 2 dose) 38%Disease control rate (combination cohort, Phase 2 dose) 97%Initial median overall survival (combination cohort, Phase 2 dose) 13.2 monthsMedian overall survival (monotherapy cohort) 6.5 monthsPatients in trial 101Expected survival in late-line relapsed/refractory AML <2.5 months
|
|||
| 18 Nov 25 | Holding | Holding(s) in Company | |
| 07 Nov 25 | Holding | Holding(s) in Company | |
| 03 Nov 25 | New LYT-200 AML Data + Update at ASH
LYT-200 Phase 1b trial shows >30% complete response rate in combination arm for relapsed/refractory AML with favorable safety. |
−1.7% | |
|
Complete response rate (combination arm) >30%Complete responses achieved (combination arm) 12 out of 39 patientsComplete responses achieved (monotherapy arm) 1 out of 31 patientsStandard of care CR rate comparison 6-12%Median prior lines of treatment 3 (range 1-7)Maintained partial response duration 24 months
|
|||
| 22 Oct 25 | New IPF Data Show Benefit in Older Patients
Phase 2b data show deupirfenidone maintains safety and efficacy in IPF patients aged 75 and older. |
+0.1% | |
|
Patients aged ≥75 years in analysis n=91Patients aged <75 years in analysis n=166Nausea rate (deupirfenidone 825mg, ≥75 years) 18.2%Nausea rate (deupirfenidone 825mg, <75 years) 21.4%IPF patients treated in U.S. as of 2019 ~25%Median survival following IPF diagnosis 2-5 years
|
|||
| 17 Oct 25 | Holding | Holding(s) in Company | |
| 14 Oct 25 | Holding | Holding(s) in Company | |
| 10 Oct 25 | Holding | Holding(s) in Company | |
| 09 Oct 25 | Holding | Holding(s) in Company | |
| 01 Oct 25 | Holding | Holding(s) in Company | |
| 29 Sep 25 | New IPF Data Show Switch Patients Stabilized
Phase 2b open-label extension data show deupirfenidone stabilized lung function in IPF patients who switched from placebo or pirfenidone. |
+3.7% | |
|
FVC decline at 26 weeks (deupirfenidone 825 mg vs placebo vs pirfenidone) -21.5 mL vs -112.5 mL vs -51.6 mLFVC difference between deupirfenidone and placebo at 26 weeks 91 mLOverall FVC decline over 52 weeks (deupirfenidone 825 mg, Part B) -32.8 mLParticipants enrolled in open-label extension 170 (>90%)Mean FVC change, switched from placebo cohort +20.0 mLMean FVC change, switched from pirfenidone cohort -23.1 mL
|
|||
| 24 Sep 25 | Director dealing | PDMR Dealing - Purchase Of Shares | |
| 23 Sep 25 | Holding | Holding(s) in Company | |
| 19 Sep 25 | Holding | Holding(s) in Company | |
| 19 Sep 25 | Holding | Holding(s) in Company | |
| 11 Sep 25 | PRTC's Seaport Advances 2nd Candidate Into Clinic
Seaport Therapeutics, a PureTech Founded Entity, dosed first participant in Phase 1 study of GlyphAgo for generalized anxiety disorder. |
−1.0% | |
|
Therapeutic candidate advancement Second candidate into clinical development
|
|||
| 04 Sep 25 | Holding | Holding(s) in Company | |
| 01 Sep 25 | Routine | Total Voting Rights | |
| 28 Aug 25 | Results | Half-year Results
Half-year results show portfolio progress with $319.6M cash, operating expenses down to $49.8M, and runway into 2028. |
−5.5% |
|
PureTech level cash, cash equivalents and short-term investments $319.6M ($366.8M)Consolidated cash, cash equivalents and short-term investments $319.9M ($367.3M)Operating expenses (H1 2025) $49.8M ($66.7M)Operational runway into 2028
|
|||
| 21 Aug 25 | PureTech Showcases Differentiated IPF Strategy
PureTech presented Phase 2b data for deupirfenidone in IPF and patient preference insights supporting Phase 3 advancement. |
+0.3% | |
|
Phase 2b trial duration 26 weeksPatients preferring greater efficacy over tolerability 69%Patients willing to discuss new treatment with physician 94%IPF patients interviewed 16
|
|||
| 18 Aug 25 | Routine | Notice of Results | |
| 13 Aug 25 | Results | PRTC's Vedanta Announces VE202 Phase 2 Results
Vedanta's VE202 Phase 2 trial for ulcerative colitis did not meet primary endpoint of endoscopic response. |
+5.2% |
|
VE202 study enrollment 114 patientsVE202 endoscopic response vs placebo not statistically differentVE303 Phase 2 absolute risk reduction vs placebo 30.5%PureTech ownership stake in Vedanta (fully diluted) 4.2%
|
|||
| 12 Aug 25 | PRTC Launches Celea to Advance Ph3-Ready IPF Drug
PureTech launches Celea Therapeutics to develop deupirfenidone for idiopathic pulmonary fibrosis, appointing former Teva CEO as leader. |
−1.9% | |
|
Teva North America specialty business $8 billionCombined peak global sales for approved IPF drugs $5 billionIPF patients receiving approved therapies in US approximately 25%
|
|||
| 05 Aug 25 | Holding | Holding(s) in Company | |
| 01 Aug 25 | Routine | Total Voting Rights | |
| 17 Jul 25 | PRTC’s Seaport Begins Phase 2b Study in MDD
Seaport Therapeutics begins Phase 2b BUOY-1 study of GlyphAllo for major depressive disorder. |
+1.3% | |
|
Phase 2b study enrollment approximately 360 patientsTreatment period 6 weeksAllopregnanolone exposure vs prior oral approximately 9 times greater
|
|||
| 16 Jul 25 | Leadership Transition
Chief Executive Officer Bharatt Chowrira stepped down; Robert Lyne appointed Interim CEO. |
+2.7% | |
| 08 Jul 25 | Board change | Directorate Change
Raju Kucherlapati stepped down as Board Chair after nearly two decades; Sharon Barber-Lui appointed Interim Chair. |
+0.3% |
| 04 Jul 25 | Director dealing | Director/PDMR Shareholding | |
| 04 Jul 25 | Director dealing | PDMR Notification RSU Vesting | |
| 04 Jul 25 | Director dealing | PDMR Notification RSU Vesting | |
| 01 Jul 25 | Routine | Total Voting Rights | |
| 26 Jun 25 | PRTC'S Vor Announces RemeGen License & $175M PIPE
Vor Bio licenses late-stage autoimmune asset telitacicept from RemeGen for $125m upfront plus $4bn milestones; raises $175m PIPE. |
+3.2% | |
|
Initial payment to RemeGen $125 millionUpfront payment $45 millionWarrant consideration $80 millionPotential regulatory and commercial milestones exceeding $4 billionPIPE gross proceeds $175 millionPureTech ownership in Vor Bio 2.1%
|
|||
| 16 Jun 25 | Routine | Result of AGM | |
| 29 May 25 | Holding | Holding(s) in Company | |
| 22 May 25 | PRTC to Present at Jefferies Healthcare Conference
PureTech executives to present at Jefferies Global Healthcare Conference on 5 June 2025. |
−0.4% | |
| 21 May 25 | IPF Data Support Lung Function Stabilization
Deupirfenidone slowed lung function decline in IPF patients to healthy adult rates over 6 months with durable effect at 52 weeks. |
+4.3% | |
|
ahead expectations FVC decline at 26 weeks (deupirfenidone 825 mg TID) -21.5 mLFVC decline at 26 weeks (placebo) -112.5 mLTreatment effect versus placebo 80.9%FVC decline over 52 weeks (open-label extension) -32.8 mLPatients in OLE with 52 weeks treatment 101Hazard ratio for time to IPF progression vs placebo 0.439 (p=0.0023)
|
|||
| 09 May 25 | PRTC Publishes Research on Unmet IPF Patient Needs
PureTech publishes research on unmet needs in idiopathic pulmonary fibrosis patient care and quality of life. |
+1.1% | |
| 01 May 25 | Results | PRTC To Present Ph2b IPF Results at ATS Conference
Phase 2b ELEVATE IPF trial results show deupirfenidone stabilized lung function decline at 26 weeks versus placebo. |
+5.4% |
|
Participants randomized 257Treatment period 26 weeksDeupirfenidone dose (higher) 825 mg TIDComparator pirfenidone dose 801 mg TIDIPF patients in US and EU5 230,000+
|
|||
| 30 Apr 25 | Results | Final Results
PureTech reports positive Phase 2b results for deupirfenidone in IPF, Cobenfy FDA approval, and $325m Seaport financing. |
−2.2% |
|
PureTech level cash, cash equivalents, and short-term investments $366.8 millionConsolidated cash, cash equivalents, and short-term investments (December 31, 2024) $367.3 millionPureTech level cash, cash equivalents, and short-term investments (March 31, 2025) $339.1 millionFounded Entities capital raised in 2024 $397.5 millionSeaport Therapeutics total capital raised $326 millionMilestone payments from Cobenfy FDA approval $29 million
|
|||
| 23 Apr 25 | Routine | Notice of Results | |
| 11 Apr 25 | Holding | Holding(s) in Company | |
| 09 Apr 25 | Routine | Form 8.3 - Puretech Health plc | |
| 09 Apr 25 | PRTC Appoints Peel Hunt Joint UK Corporate Broker
PureTech appoints Peel Hunt as joint UK corporate broker alongside UBS. |
−12.4% | |
| 08 Apr 25 | Routine | Form 8.3 - PureTech Health plc | |
| 08 Apr 25 | Routine | PureTech... | |
| 08 Apr 25 | Routine | Form 8.3 - Puretech Health plc | |
| 08 Apr 25 | Routine | Form 8.3 - Puretech Health plc | |
| 08 Apr 25 | Routine | Form 8.3 - [puretech Health plc | |
| 08 Apr 25 | Routine | Form 8.3 - Puretech Health plc | |
| 07 Apr 25 | Rule 2.8 Announcement
Nordic Capital XI withdrew its acquisition proposal for PureTech after Board rejection and confirmed it will not make an offer. |
+7.0% | |
| 07 Apr 25 | Offer | Statement re Possible Offer
PureTech in discussions with Nordic Capital regarding possible cash offer to acquire entire share capital. |
+7.0% |
| 11 Mar 25 | PRTC's Seaport Adds Finance/Operations Exec to BOD
Seaport Therapeutics appoints Robert Hombach, former Baxalta CFO, to board as Audit Committee Chair. |
−4.0% | |
| 03 Mar 25 | Routine | Total Voting Rights | |
| 27 Feb 25 | Director dealing | PDMR Notification RSU Vesting | |
| 25 Feb 25 | PRTC Presents at Leerink Partners Healthcare Conf
PureTech CEO and co-founder to present at Leerink Partners Global Healthcare Conference on March 11. |
−0.8% | |
| 12 Feb 25 | PRTC's Seaport Publishes New Glyph Platform Data
Seaport Therapeutics publishes research showing Glyph platform achieves up to 55% lymphatic drug absorption with improved linker performance. |
+0.4% | |
|
Lymphatic drug absorption with new attachment point up to 55%Higher release in lymph nodes vs previous linkers up to two-fold
|
|||
| 27 Jan 25 | PRTC's Vedanta Publishes Ph2 in Nature Medicine
Vedanta's VE303 Phase 2 data published in Nature Medicine showing mechanism of action through multiple pathways for recurrent CDI prevention. |
+2.6% | |
|
VE303 reduction in CDI recurrence odds vs placebo more than 80%
|
|||
| 09 Jan 25 | PRTC's LYT-200 Gets Fast Track Designation in AML
LYT-200 anti-galectin-9 monoclonal antibody receives FDA Fast Track designation for acute myeloid leukemia treatment. |
+2.1% | |
| 08 Jan 25 | PureTech to Present at the JP Morgan Conference
PureTech CEO to present at J.P. Morgan Healthcare Conference on 15 January 2025. |
−4.4% | |
| 06 Jan 25 | PureTech Appoints UBS as UK Corporate Broker
PureTech Health appoints UBS as UK Corporate Broker. |
−0.4% | |
| 16 Dec 24 | PRTC's Ph2b in IPF Successful; New SOC Potential
PureTech's deupirfenidone achieved primary and key secondary endpoints in Phase 2b IPF trial, showing superior efficacy to pirfenidone. |
+4.4% | |
|
FVC decline with deupirfenidone 825 mg TID -21.5 mL (-51.6 mL (pirfenidone))Treatment effect versus placebo (deupirfenidone 825 mg TID) 80.9% (54.1% (pirfenidone))Primary endpoint posterior probability 98.5%Key secondary endpoint posterior probability 99.6%FVC decline placebo -112.5 mLTrial duration 26 weeks
|
|||
| 11 Dec 24 | Holding | Holding(s) in Company | |
| 11 Dec 24 | PRTC's Seaport Presents Ph1 SPT-300 Data at ACNP
Seaport presented Phase 1 data for SPT-300 showing well-tolerated doses with pharmacodynamic activity; Phase 2b in major depressive disorder planned. |
−0.5% | |
|
Phase 1 study participants 99SPT-300 blood levels vs unmodified allopregnanolone approximately 9 times greaterSomnolence severity mild and transient
|
|||
| 09 Dec 24 | PRTC Presents LYT-200 Phase 1b Data in AML at ASH
LYT-200 Phase 1b data shows safety and clinical benefit in relapsed/refractory AML/MDS as monotherapy and in combination. |
+4.1% | |
|
Monotherapy arm: stable disease or better 59%Monotherapy arm: partial responses 2Monotherapy evaluable patients 22Combination arm: stable disease or better 80%Combination arm: complete responses 2Combination evaluable patients 15
|
|||
| 27 Nov 24 | Holding | Holding(s) in Company | |
| 27 Nov 24 | Holding | Holding(s) in Company | |
| 20 Nov 24 | PRTC's Seaport Adds Microsoft and J&J Exec to BOD
Seaport Therapeutics, a PureTech founded entity, appoints Sandi Peterson to its Board of Directors. |
−0.1% | |
| 05 Nov 24 | Board change | PRTC's Seaport Adds Biotech Finance Exec as CFO
Seaport Therapeutics, a PureTech founded entity, appoints Lauren White as Chief Financial Officer. |
−1.8% |
| 01 Nov 24 | Routine | Total Voting Rights | |
| 31 Oct 24 | Director dealing | Director/PDMR Shareholding | |
| 30 Oct 24 | PRTC to Present at UBS and Jefferies Conferences
PureTech management to present at UBS and Jefferies investor conferences in November. |
+0.4% | |
| 21 Oct 24 | PRTC's Seaport Closes $225M Series B Financing
Seaport Therapeutics, a PureTech Founded Entity, closes $225 million Series B financing round led by General Atlantic. |
+2.8% | |
|
Series B financing $225mTotal capital raised by Seaport since launch $325mPureTech ownership stake post-Series B 36.7%
|
|||
| 09 Oct 24 | PRTC's IPF Patient Research & Ph 2b On Track YE24
Phase 2b ELEVATE IPF trial data on LYT-100 expected end of 2024; patient research presented at CHEST conference. |
+0.5% | |
|
IPF patient survey size 90 participantsPatients reporting shortness of breath 86%Patients reporting fatigue 78%Patients reporting cough 77%ILD center patients discussed both antifibrotics 76%Community practice patients discussed both antifibrotics 56%
|
|||
| 01 Oct 24 | PRTC to Give 3 Presentations at CHEST 2024 Meeting
PureTech to present three studies on LYT-100 for IPF at CHEST 2024 meeting in Boston. |
−3.7% | |
| 27 Sep 24 | KarXT/Cobenfy Approved by FDA; PRTC Receives $29M
KarXT receives FDA approval for schizophrenia treatment; PureTech receives $29M in milestone payments. |
+2.7% | |
|
Milestone payments to PureTech $29mRoyalty rate on net annual sales over $2 billion approximately 2%Total proceeds generated by PureTech to date approximately $1.1 billionCapital directed toward Karuna founding and Cobenfy development $18.5 million
|
|||
| 06 Sep 24 | Holding | Holding(s) in Company | |
| 06 Sep 24 | PRTC's Vor Shares New AML Data Validating Approach
Vor Bio announced Phase 1/2 data showing trem-cel plus Mylotarg achieved engraftment and shielding in relapsed/refractory AML patients. |
−3.6% | |
|
Patients treated with trem-cel 18Patients receiving Mylotarg 10Primary neutrophil engraftment rate 100%Median neutrophil engraftment time 9 daysMedian platelet recovery time 16.5 daysMedian CD33 editing efficiency 89%
|
|||
| 28 Aug 24 | Results | Half-year Results
Half-year results show progress across portfolio with $150m shareholder returns and strong cash position of $400.6m. |
+2.8% |
|
PureTech Level cash, cash equivalents and short-term investments $400.6m ($326.0m)Operating expenses (six months) $66.7m ($79.3m)Consolidated cash, cash equivalents and short-term investments $500.4m ($327.1m)Capital returned to shareholders since May 2022 $150mExpected operational runway at least three yearsGross proceeds from Karuna equity position approximately $293m
|
|||
| 28 Aug 24 | Results of AGM on 13 June 2024 – Update Statement
AGM resolutions approved but more than 20% voted against remuneration and director re-election items. |
+2.8% | |
| 22 Aug 24 | PRTC Adds Industry Leader to Board of Directors
Michele Holcomb, healthcare executive with 30 years experience, joins board as independent non-executive director. |
−0.2% | |
| 21 Aug 24 | Routine | Notice of Results | |
| 13 Aug 24 | PRTC's Seaport Appoints Global Pharma Exec to BOD
Seaport Therapeutics appoints David Wheadon, experienced pharma executive, to board of directors. |
+0.7% | |
| 23 Jul 24 | PRTC'S Vedanta Expands Leadership Team
Vedanta Biosciences appoints Head of Commercial and two other senior leadership roles. |
+0.5% | |
| 01 Jul 24 | Holding | Holding(s) in Company | |
| 27 Jun 24 | Director dealing | PDMR Notification RSU Vesting | |
| 27 Jun 24 | Director dealing | Director/PDMR Shareholding | |
| 24 Jun 24 | Completion of Tender Offer & Total Voting Rights
Tender offer completed; Company repurchased and will cancel 31.5 million shares for $100 million. |
−5.1% | |
|
Tender Offer value $100 millionShares repurchased 31,540,670Tender Price per share 250 penceIssued Ordinary Share Capital after cancellation 239,318,580
|
|||
| 24 Jun 24 | Result of Tender Offer
PureTech completed tender offer to repurchase 31.5m shares for $100m at 250 pence per share. |
−5.1% | |
|
Shares repurchased 31,540,670Tender price per share 250 penceTotal cost $100 millionPercentage of issued capital approximately 12%Issued share capital after 239,318,580 shares
|
|||
| 20 Jun 24 | Director Declaration
Raju Kucherlapati appointed permanent Chair of Board after serving as interim Chair since June 2023. |
+0.0% | |
| 18 Jun 24 | PRTC's Seaport Appoints Seasoned Execs to Team
Seaport Therapeutics appoints Antony Loebel as Chief Medical Officer and Lana Gladstein as General Counsel. |
−2.1% | |
| 13 Jun 24 | Routine | Result of AGM | |
| 07 Jun 24 | Holding | Holding(s) in Company | |
| 06 Jun 24 | Routine | Result of Meeting | |
| 04 Jun 24 | Additional Disclosure Re: Tender Offer
Company files amended Schedule TO clarifying $100 million tender offer at 250 pence per share and shareholder notification requirements. |
−2.5% | |
|
Tender Offer Size $100 millionTender Offer Price 250 pence per Ordinary Share
|
|||
| 03 Jun 24 | Routine | Total Voting Rights | |
| 29 May 24 | PRTC's Akili Enters Into Merger Agreement
PureTech's founded entity Akili to merge with Virtual Therapeutics in all-cash deal at $0.4340 per share. |
+1.1% | |
|
Akili share purchase price $0.4340 per sharePremium to May 28, 2024 close 4%Premium to April 29, 2024 close 85%PureTech's Akili shareholding as of May 7, 2024 12,527,477 shares
|
|||
| 23 May 24 | PRTC to Present at Jefferies Healthcare Conference
CEO and Co-founder to participate in fireside chat at Jefferies Global Healthcare Conference. |
−0.4% | |
| 21 May 24 | PRTC's Vedanta Begins Phase 3 of VE303 in C. diff
Vedanta Biosciences enrolled first patient in Phase 3 RESTORATiVE303 trial of VE303 for recurrent C. difficile infection prevention. |
−1.1% | |
|
Phase 2 CONSORTIUM trial: adjusted absolute risk reduction 30.5%Phase 2 CONSORTIUM trial: reduction in odds of CDI recurrence greater than 80%RESTORATiVE303 trial sites approximately 200 sites in 22 countries
|
|||
| 20 May 24 | Tender Offer
PureTech launches $100 million tender offer to repurchase up to 12% of shares at 250 pence per share. |
+3.9% | |
|
Tender offer size $100 millionTender price per ordinary share 250 penceShares offered for repurchase up to 33,500,000 ordinary sharesPercentage of issued capital approximately 12%Premium to 3-day VWAP (19 March 2024) 25%Premium to closing price (16 May 2024) 12.6%
|
|||
| 09 May 24 | PRTC's Seaport Presents Ph1 and Ph2a SPT-300 Data
Seaport's SPT-300 showed nine times greater allopregnanolone exposure than published oral data and reduced stress-induced cortisol in Phase 2a. |
+0.7% | |
|
SPT-300 allopregnanolone exposure vs published oral data 9x greaterPhase 1 trial participants 99
|
|||
| 07 May 24 | PRTC's Seaport Announces Board/Team Appointments
Seaport Therapeutics appoints Denice Torres to board, Eric Green as COO and Michael Chen as Chief Scientific Officer. |
+1.4% | |
|
Seaport Series A financing $100 millionPureTech equity ownership in Seaport (diluted) 61.5%
|
|||
| 01 May 24 | Routine | Total Voting Rights | |
| 25 Apr 24 | Results | Final Results
Full year 2023 results show operational progress across internal programs and founded entities, with Karuna acquired by Bristol Myers Squibb for $14 billion. |
+0.0% |
|
PureTech level cash, cash equivalents and short-term investments (Dec 31, 2023) $326.0 millionPureTech level cash, cash equivalents and short-term investments (Mar 31, 2024) $573.3 millionKaruna acquisition price by Bristol Myers Squibb $14.0 billionSeaport Series A financing $100 millionPureTech gross proceeds from Karuna equity position $293 millionRoyalty Pharma agreement for KarXT royalties up to $500 million
|
|||
| 18 Apr 24 | Routine | Notice of Results | |
| 16 Apr 24 | Results | PRTC LYT-100 Ph2b in IPF Enrolled; Results Q4 2024
PureTech completes enrollment in Phase 2b ELEVATE IPF trial of LYT-100; topline results expected Q4 2024. |
−1.4% |
|
Trial participants enrolled completedLYT-100 dose arms in trial 550 mg and 825 mg TIDTreatment duration up to 26 weeksGI and CNS adverse event reduction at 550 mg approximately 50 percent vs pirfenidonePatients with IPF foregoing treatment approximately 75 percent in U.S.IPF median survival 2-5 years
|
|||
| 11 Apr 24 | FDA Grants PRTC's LYT-200 Fast Track Designation
FDA grants Fast Track designation for LYT-200 in head and neck cancers in combination with anti-PD1 therapy. |
−0.2% | |
|
Annual head and neck cancer diagnoses in US approximately 66,000Median survival rate for metastatic head and neck cancer about ten months
|
|||
| 09 Apr 24 | PRTC Launches Seaport w/ $100M; Leadership Changes
PureTech launches Seaport Therapeutics with $100m Series A funding and announces management transitions. |
−0.2% | |
|
Seaport Series A financing $100 millionPureTech equity ownership in Seaport post-financing 61.5%Karuna acquisition price by Bristol Myers Squibb $14 billionGross proceeds to PureTech from Karuna to date approximately $1.1 billionPureTech's initial investment in Karuna $18.5 millionPotential milestone payments from Royalty Pharma up to $400 million
|
|||
| 19 Mar 24 | $100M Tender Offer
PureTech proposes $100 million tender offer at 250 pence per share, funded by Karuna Therapeutics sale proceeds. |
+9.3% | |
|
Tender Offer amount $100 millionTender Offer price per share 250 pencePremium to trailing three-day VWAP 25%Percentage of market capitalization approximately 14%Gross proceeds from Karuna stake approximately $293 millionTotal capital returned (buyback + tender) $150 million
|
|||
| 18 Mar 24 | $14B Acquisition of PRTC’s Karuna by BMS Completed
Bristol Myers Squibb completed acquisition of PureTech-founded Karuna Therapeutics for $14 billion, acquiring KarXT for schizophrenia. |
+3.8% | |
|
Acquisition price for Karuna $14 billionPrice per share $330.00PureTech's gross proceeds from equity position approximately $293 millionPureTech's original investment in Karuna approximately $18.5 millionTotal direct cash proceeds generated by PureTech from Karuna approximately $1.1 billionPotential milestone payments from Royalty Pharma up to $400 million
|
|||
| 13 Mar 24 | FDA Grants PRTC's LYT-200 Orphan Drug Designation
FDA grants orphan drug designation for LYT-200 in acute myeloid leukemia, qualifying for seven-year market exclusivity. |
−2.9% | |
|
Designation Orphan Drug Designation for AMLMarket exclusivity period 7 years in the U.S.Patient population threshold Fewer than 200,000 persons in the U.S.
|
|||
| 06 Mar 24 | Director dealing | PDMR Notification RSU Vesting | |
| 27 Feb 24 | PRTC to Present at Cowen and Leerink Conferences
PureTech management to present at TD Cowen and Leerink Partners investor conferences in March 2024. |
−0.2% | |
| 27 Feb 24 | Akili Positive Ph3 & Japan PMDA Submission
Akili's digital therapeutic SDT-001 submitted for marketing approval in Japan following positive Phase 3 results. |
−0.2% | |
|
Phase 3 trial patients 164 pediatric ADHD patients aged 6 to 17Treatment duration approximately 25 minutes once daily for 6 weeksPrimary endpoint achievement statistically significant improvement in ADHD-RS-IV Inattention score (p < 0.05)Secondary endpoints statistically significant improvements in total ADHD-RS-IV and hyperactivity/impulsivity scores (p < 0.05)
|
|||
| 08 Feb 24 | Routine | Transaction in Own Shares | |
| 07 Feb 24 | Routine | Transaction in Own Shares | |
| 06 Feb 24 | Routine | Transaction in Own Shares | |
| 05 Feb 24 | Routine | Transaction in Own Shares | |
| 02 Feb 24 | Routine | Transaction in Own Shares | |
| 01 Feb 24 | Routine | Transaction in Own Shares | |
| 31 Jan 24 | Routine | Transaction in Own Shares | |
| 30 Jan 24 | Routine | Transaction in Own Shares | |
| 29 Jan 24 | Routine | Transaction in Own Shares | |
| 26 Jan 24 | Routine | Transaction in Own Shares | |
| 25 Jan 24 | Routine | Transaction in Own Shares | |
| 24 Jan 24 | Routine | Transaction in Own Shares | |
| 23 Jan 24 | Routine | Transaction in Own Shares | |
| 22 Jan 24 | Routine | Transaction in Own Shares | |
| 19 Jan 24 | Routine | Transaction in Own Shares | |
| 18 Jan 24 | Routine | Transaction in Own Shares | |
| 17 Jan 24 | Routine | Transaction in Own Shares | |
| 16 Jan 24 | Routine | Transaction in Own Shares | |
| 15 Jan 24 | Routine | Transaction in Own Shares | |
| 12 Jan 24 | Routine | Transaction in Own Shares | |
| 11 Jan 24 | Routine | Transaction in Own Shares | |
| 10 Jan 24 | Routine | Transaction in Own Shares | |
| 09 Jan 24 | Routine | Transaction in Own Shares | |
| 08 Jan 24 | Routine | Transaction in Own Shares | |
| 05 Jan 24 | Routine | Transaction in Own Shares | |
| 04 Jan 24 | Routine | Transaction in Own Shares | |
| 03 Jan 24 | PureTech to present at the JP Morgan Conference
CEO to present at J.P. Morgan Healthcare Conference on 10 January 2024. |
+3.7% | |
| 03 Jan 24 | Routine | Transaction in Own Shares | |
| 27 Dec 23 | Routine | Transaction in Own Shares | |
| 22 Dec 23 | BMY Acquires PRTC Founded Entity Karuna for $14B
Bristol Myers Squibb to acquire PureTech-founded entity Karuna Therapeutics for $14 billion in cash. |
+21.0% | |
|
Acquisition price per share $330.00Total equity value $14.0 billionNet of estimated cash acquired $12.7 billionKarXT PDUFA date September 26, 2024
|
|||
| 22 Dec 23 | Routine | Transaction in Own Shares | |
| 21 Dec 23 | Routine | Transaction in Own Shares | |
| 20 Dec 23 | PRTC Year End Update & Outlook for 2024
PureTech reports 2023 progress and launches two new Founded Entities; cash runway extended to 2027. |
+0.5% | |
|
Consolidated Cash, Cash Equivalents and Short-Term Investments at year end approximately $320 millionRoyalty Pharma deal value up to $500 millionNon-dilutive proceeds generated since 2020 over $800 millionClinical trial success rate 80%
|
|||
| 20 Dec 23 | Routine | Transaction in Own Shares | |
| 19 Dec 23 | Routine | Transaction in Own Shares | |
| 18 Dec 23 | Routine | Transaction in Own Shares | |
| 15 Dec 23 | Routine | Transaction in Own Shares | |
| 14 Dec 23 | Routine | Transaction in Own Shares | |
| 13 Dec 23 | Routine | Transaction in Own Shares | |
| 11 Dec 23 | Routine | Transaction in Own Shares | |
| 08 Dec 23 | Routine | Transaction in Own Shares | |
| 07 Dec 23 | New LYT-200 Solid Tumors Data Presented at ESMO-IO
LYT-200 Phase 1 data shows favorable safety and anti-tumor activity in combination with tislelizumab in solid tumors. |
−2.3% | |
|
Patients with head and neck cancer showing disease control 3 of 4Complete response duration in head and neck cancer 9 monthsPartial response duration in head and neck cancer 8 monthsMonotherapy patients dosed 20Combination arm patients dosed 11
|
|||
| 07 Dec 23 | Routine | Transaction in Own Shares | |
| 06 Dec 23 | Routine | Transaction in Own Shares | |
| 05 Dec 23 | Routine | Transaction in Own Shares | |
| 04 Dec 23 | Routine | Transaction in Own Shares | |
| 01 Dec 23 | Routine | Transaction in Own Shares | |
| 30 Nov 23 | Routine | Transaction in Own Shares | |
| 29 Nov 23 | Karuna's NDA for KarXT Accepted by U.S. FDA
FDA accepts NDA for Karuna's KarXT schizophrenia treatment with PDUFA decision date of September 26, 2024. |
+0.5% | |
|
PDUFA action date September 26, 2024Clinical trials completed 5 trials (EMERGENT-1 through EMERGENT-5)Primary endpoint met All three placebo-controlled trials
|
|||
| 29 Nov 23 | Routine | Transaction in Own Shares | |
| 28 Nov 23 | Routine | Transaction in Own Shares | |
| 27 Nov 23 | Routine | Transaction in Own Shares | |
| 24 Nov 23 | Routine | Transaction in Own Shares | |
| 23 Nov 23 | Routine | Transaction in Own Shares | |
| 22 Nov 23 | Routine | Transaction in Own Shares | |
| 21 Nov 23 | Routine | Transaction in Own Shares | |
| 20 Nov 23 | Routine | Transaction in Own Shares | |
| 17 Nov 23 | Karuna's Blood Pressure Trial of KarXT Successful
Karuna's Phase 1b trial shows KarXT did not cause clinically meaningful blood pressure increases in schizophrenia patients. |
−2.8% | |
|
Mean change in 24-hour ambulatory systolic blood pressure at week 8 -0.59 mmHgUpper bound of 95% confidence interval 1.60 mmHgFDA-defined clinically meaningful increase threshold ≥3 mmHgTrial participants enrolled 133 adultsParticipants at highest dose level KarXT 125/30 ~80%
|
|||
| 17 Nov 23 | Routine | Transaction in Own Shares | |
| 15 Nov 23 | Routine | Transaction in Own Shares | |
| 14 Nov 23 | PRTC Achieves Primary Endpoint in Anxiety Trial
LYT-300 achieved primary endpoint in Phase 2a anxiety trial with statistically significant cortisol reduction versus placebo. |
+3.9% | |
|
Primary endpoint: cortisol reduction vs placebo p=0.0001Effect size (Cohen's d) 0.72Healthy volunteers randomized 80
|
|||
| 14 Nov 23 | Routine | Transaction in Own Shares | |
| 13 Nov 23 | Routine | Transaction in Own Shares | |
| 10 Nov 23 | Routine | Transaction in Own Shares | |
| 09 Nov 23 | Routine | Transaction in Own Shares | |
| 08 Nov 23 | Routine | Transaction in Own Shares | |
| 07 Nov 23 | Routine | Transaction in Own Shares | |
| 06 Nov 23 | Routine | Transaction in Own Shares | |
| 03 Nov 23 | Routine | Transaction in Own Shares | |
| 02 Nov 23 | Routine | Transaction in Own Shares | |
| 01 Nov 23 | Routine | Transaction in Own Shares | |
| 31 Oct 23 | Routine | Transaction in Own Shares | |
| 30 Oct 23 | Routine | Transaction in Own Shares | |
| 27 Oct 23 | Routine | Transaction in Own Shares | |
| 26 Oct 23 | Routine | Transaction in Own Shares | |
| 25 Oct 23 | Routine | Transaction in Own Shares | |
| 24 Oct 23 | Routine | Transaction in Own Shares | |
| 23 Oct 23 | Routine | Transaction in Own Shares | |
| 20 Oct 23 | Routine | Transaction in Own Shares | |
| 19 Oct 23 | Routine | Transaction in Own Shares | |
| 18 Oct 23 | Routine | Transaction in Own Shares | |
| 17 Oct 23 | PRTC to Present at Upcoming Conferences + Progress
PureTech reports Q3 progress across pipeline with multiple data readouts expected by end-2023 and expanded CNS focus. |
+0.5% | |
|
CNS pipeline programs 7Funding awarded for LYT-300 in FXTAS $11.4 million
|
|||
| 17 Oct 23 | Routine | Transaction in Own Shares | |
| 16 Oct 23 | Routine | Transaction in Own Shares | |
| 13 Oct 23 | Routine | Transaction in Own Shares | |
| 12 Oct 23 | Routine | Transaction in Own Shares | |
| 11 Oct 23 | New LYT-100 Data from Phase 1 Trials at Conference
LYT-100 showed ~50% fewer GI and CNS adverse events than pirfenidone at equivalent exposure in Phase 1 healthy older adults. |
−4.1% | |
|
LYT-100 dose (three times daily) 550 mgPirfenidone FDA-approved dose (three times daily) 801 mgReduction in GI/CNS adverse events ~50%Peak drug concentration reduction 24% lowerHigher LYT-100 dose evaluated 824 mg TIDHigher dose exposure increase 43%
|
|||
| 11 Oct 23 | Routine | Transaction in Own Shares | |
| 10 Oct 23 | Routine | Transaction in Own Shares | |
| 09 Oct 23 | Routine | Transaction in Own Shares | |
| 06 Oct 23 | Routine | Transaction in Own Shares | |
| 05 Oct 23 | Routine | Transaction in Own Shares | |
| 04 Oct 23 | Vedanta VE202 Ph2 Starts + Fast Track Designation
Vedanta VE202 Phase 2 trial started for ulcerative colitis and received FDA Fast Track designation. |
||
|
VE202 study design Phase 2 COLLECTiVE202, 100 patients, mild-to-moderate UCVE202 composition 16 bacterial strains consortium
|
|||
| 04 Oct 23 | Routine | Transaction in Own Shares | |
| 03 Oct 23 | Routine | Transaction in Own Shares | |
| 02 Oct 23 | Routine | Transaction in Own Shares | |
Company filings. Not investment advice.